WORLD JOURNAL OF PLASTIC SURGERY
Sun, Apr 28, 2024
[Archive]
Volume 12, Issue 3 (2023)
WJPS 2023, 12(3): 106-110 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Shimabukuro M, Ishii N, Ko T, Kishi K. A Case of Refractory Heel Ulcer Complicated by Moderate Osteomyelitis and Cellulitis Successfully Treated With Rheocarna. WJPS 2023; 12 (3) :106-110
URL: http://wjps.ir/article-1-1199-en.html
URL: http://wjps.ir/article-1-1199-en.html
1- Department of Plastic and Reconstructive Surgery, International University of Health and Welfare Hospital, Tochigi, Japan
2- Department of Plastic and Reconstructive Surgery, International University of Health and Welfare, School of Medicine, Chiba, Japan , ishinao0916@gmail.com
3- Department of Plastic and Reconstructive Surgery, Keio University, Tokyo, Japan
2- Department of Plastic and Reconstructive Surgery, International University of Health and Welfare, School of Medicine, Chiba, Japan , ishinao0916@gmail.com
3- Department of Plastic and Reconstructive Surgery, Keio University, Tokyo, Japan
Abstract: (892 Views)
Revascularization surgery was first considered for the treatment of ulcers in patients with critical limb ischemia (CLI). However, it may not be indicated for patients with severe infections or peripheral vascular occlusions. Although blood purification therapy is adjuvant therapy for such patients, it is not yet widely used due to insurance coverage. We report a case of a refractory heel ulcer with moderate osteomyelitis and cellulitis that was not amenable to revascularization. Treatment with the adsorptive blood purifier rheocarna® (Kaneka Corporation; Osaka, Japan) resulted in complete epithelialization of the ulcer and control of inflammation. Although this case required careful follow-up, we believe rheocarna might be a promising treatment option for patients with CLI who do not respond to revascularization. Rheocarna could improve peripheral blood flow and control inflammation by improving antibiotic drug delivery.
Keywords: Arteriosclerosis obliterans, Blood purification therapy, Critical limb ischemia, Osteomyelitis
References
1. Michael SC, Andrew WB, Philippe K, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. J Vasc Surg 2019;69:3S-125S.e40.
2. Kobori M, Oiwa K, Yagi H, et al. A case in which CHDF was effective to reperfusion injury by the endovascular treatment to acute limb ischemia. J Jpn Soc Blood Purif Crit Care 2011;2:213-218.
3. Tsurumi-Ikeya Y, Tamura K, Azuma K, et al. Sustained Inhibition of Oxidized Low-Density Lipoprotein Is Involved in the Long-Term Therapeutic Effects of Apheresis in Dialysis Patients. Arterioscler Thromb Vasc Biol 2010;30:1058-1065. [DOI:10.1161/ATVBAHA.109.200212]
4. Oda O, Nagaya T, Ogawa H. Analysis of protein absorbed by LDL column (Liposorber) with special reference to complement component factor D. Clin Chim Acta 2004;342:155-160. [DOI:10.1016/j.cccn.2003.12.012]
5. Hara T, Kiyomoto H, Hitomi H, et al. Low-density lipoprotein apheresis for haemodialysis patients with peripheral arterial disease reduces reactive oxygen species production via suppression of NADPH oxidase gene expression in leucocytes. Nephrol Dial Transplant 2009;24:3818-3825. [DOI:10.1093/ndt/gfp342]
6. Kobayashi S, Furukawa M, Ichioka S, et al. A novel low-density lipoprotein/fibrinogen apheresis method for chronic limb-threatening ischemia in patients with poor options for revascularization: a multicenter, single-arm clinical trial. Ther Apher Dial 2022;27:361-369. [DOI:10.1111/1744-9987.13915]
7. Kojima S, Nakama T, Obunai K. Angiographic and clinical impact of novel low-density lipoprotein apheresis for no-option chronic limb-threatening ischemia. Ther Apher Dial 2022;27:186-187. [DOI:10.1111/1744-9987.13891]
8. Nakamura Y, Kumada Y, Kawai N, et al. Rheocarna® therapy after distal bypass surgery. SAGE Open Med 2023;11:1-5. [DOI:10.1177/20503121231192813]
9. Naganuma S, Agishi T, Miura A, et al. Hemorheological effect of LDL apheresis on atherosclerosis disease with hyperlipidemia. Jpn J Artif Organs 1992;21:1339-1343.
10. Waldmann E, Parhofer KG. Lipoprotein apheresis to treat elevated lipoprotein (a). J. Lipid Res 2016;57:1751-1757. [DOI:10.1194/jlr.R056549]
11. Taylan C, Weber LT. An update on lipid apheresis for familial hypercholesterolemia. Pediatr Nephrol 2023;38:371-382. [DOI:10.1007/s00467-022-05541-1]
12. Satake A, Nakano Y, Amano T. Rheocarna® as an alternative therapeutic option for patients with chronic limb-threatening ischemia: A case report. SAGE Open Med Case Rep 2023;11:1-5. [DOI:10.1177/2050313X221149359]
13. Fujii M, Terashi H, Yokono K, et al. The Degree of Blood Supply and Infection Control Needed to Treat Diabetic Chronic Limb-Threatening Ischemia with Forefoot Osteomyelitis. J Am Po- diatr Med Assoc 2021;111:18-185. [DOI:10.7547/18-185]
14. Krzysztof K, Krzysztof W, Tomasz K. Use of Negative Pressure Wound Therapy after Endovascular Revascularization in a Patient with Diabetic Foot Syndrome Complicated by Sepsis. Negat. Press. Wound Ther J 2015;2:8-12. [DOI:10.18487/npwtj.v2i2.17--]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
